Contribute Try STAT+ Today

Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating because that oh-so familiar routine of online calls and deadlines has returned. But what can you do? After all, the world — such as it is — continues to spin. So why not give it a nudge with a delicious cup of stimulation? Our choice today is cinnamon hazelnut. Feel free to join us. Meanwhile, here are a few tidbits to help you as your latest journey gets under way. We hope you have a productive and fulfilling day and, of course, do keep in touch. We enjoy the feedback and suggestions…

Johnson & Johnson (JNJ) plans to ask federal regulators early this week to authorize a booster shot of its Covid-19 vaccine, The New York Times reports. The company is the last of the three federally authorized vaccine providers to call for extra injections, amid mounting evidence that at least the elderly and other high-risk groups need more protection. Federal officials are increasingly worried that the more than 15 million Americans who received the J&J vaccine face too high a risk of severe Covid-19. The U.S. Food and Drug Administration on Friday scheduled an Oct. 15 meeting for an expert advisory committee to discuss whether to authorize emergency use of a J&J booster shot.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment